Updates are available Correction dated 2019-01-28
Click to view Correction: https://doi.org/10.1186/s12931-019-0985-2
-
Authors
Driessen, M. T.
Whalen, J.
Seewoodharry Buguth, B.
Vallejo-Aparicio, L. A.
Naya, I. P.
Asukai, Y. https://orcid.org/0000-0003-1837-5604
Alcázar-Navarrete, B.
Miravitlles, M.
García-Río, F.
Risebrough, N. A.
-
Funding
Funding for this research was provided by:
GlaxoSmithKline
- License Information
-
More Information
Article History
Received: 12 June 2018
Accepted: 18 October 2018
First Online: 20 November 2018
Change Date: 28 January 2019
Change Type: Correction
Change Details: Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.
Ethics approval and consent to participate
: No ethics approval was required for the study as data were taken from previously conducted studies that had obtained ethical approval.
: Not applicable.
: IPN and YA are employees of GSK and hold stocks/shares in the company. MTD was an employee of GSK and held stocks/shares in the company, at the time of the study. LAV-A is an employee of GSK. JW, BSB and NAR are employees of ICON Health Economics, who were contracted by GSK to provide data analysis for the study. JW was an employee of ICON Health Economics at the time of the study. No funding was provided to employees of ICON Health Economics for manuscript development. BA-N received personal fees and nonfinancial support from GlaxoSmithKline grants, personal fees, and nonfinancial support from Novartis AG, personal fees and nonfinancial support from Boehringer Ingelheim, personal fees and nonfinancial support from Chiesi, grants, personal fees, and nonfinancial support from Laboratorios Menarini, personal fees from Gebro, and personal fees from AstraZeneca outside the submitted work. In addition, BA-N has a patent (P201730724) pending. MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Grifols and Novartis, and consulting fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Gebro Pharma, CSL Behring, Novartis and Grifols. FG-R has received speaker fees from Boehringer Ingelheim, Novartis, Chiesi and Rovi, and consulting fees from Boehringer Ingelheim, GlaxoSmithKline, Grebo Pharma, AstraZeneca, Menarini, and Novartis.Accuhaler, Anoro, Ellipta, Flixotide, Seretide and Ventolin are owned by or licensed to the GSK group of companies. Handihaler, Respimat, Spiriva and Spiolto are trademarks of Boehringer Ingelheim International GmbH.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
